Serum AFP is widely used in clinical practice for diagnosis, pretreatment prognosis, predicting survival after transarterial chemoembolization, and tumor response to therapy, as it is considered to continuously reflect HCC tumor activity and viable burden [96]. Here, AFP is linked to hepatocellular carcinoma.